The first patients have been enrolled in a phase 1/2a clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration, according to a press release from Clearside Biomedical.
The open-label, dose-escalation OASIS trial will assess the safety and tolerability of a single dose of CLS-AX (axitinib injectable suspension) via suprachoroidal injection across three patient cohorts for 3 months. Secondary trial endpoints include evaluation of the pharmacokinetics, visual function, ocular anatomy and need for additional treatment with intravitreal aflibercept.
“We
Uncategorized